• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Cardinal Health announces the addition of Solaris Health, the country's leading urology MSO, to The Specialty Alliance

    8/12/25 6:45:00 AM ET
    $CAH
    Other Pharmaceuticals
    Health Care
    Get the next $CAH alert in real time by email
    • Adds over 750 providers to Cardinal Health's multi-specialty MSO platform, The Specialty Alliance
    • Joins with recent urology acquisitions to bolster The Specialty Alliance's leadership in the urology therapeutic area
    • Cardinal Health MSO platforms reach ~3,000 providers in 32 states upon transaction close

    DUBLIN, Ohio, Aug. 12, 2025 /PRNewswire/ -- Cardinal Health (NYSE:CAH) today announced that The Specialty Alliance, its multi-specialty management services organization (MSO) platform, has entered into a definitive agreement to acquire Solaris Health, the country's leading urology MSO, from Lee Equity Partners and Solaris Health physician owners.

    Cardinal Health Logo (PRNewsfoto/Cardinal Health)

    The transaction accelerates Cardinal Health's multi-specialty growth strategy by extending the reach of The Specialty Alliance, led by CEO James Weber, MD. Taken together with the recent acquisitions of Urology America and Potomac Urology and the just-completed acquisition of Academic Urology & Urogynecology, the acquisition of Solaris Health brings immediate scale to the Urology Alliance within The Specialty Alliance.

    Cardinal Health will provide approximately $1.9 billion in cash to The Specialty Alliance to enable the acquisition and will own approximately 75% of The Specialty Alliance after its acquisition of Solaris Health. Solaris Health physicians and several members of management will join GI Alliance physician owners and management as equity holders and operators in The Specialty Alliance.

    Solaris Health supports more than 750 providers across more than 250 practice locations in 14 states, with extensive reach into the local communities they serve. Solaris Health's resilient model and diverse revenue streams result from supporting a broad array of ancillary services, underpinned by a national MSO infrastructure.  

    "Accelerating Specialty growth remains our top priority," said Jason Hollar, CEO, Cardinal Health. "As we previously highlighted, urology is an attractive specialty for us, and we are well-positioned to meet the comprehensive needs of community urologists through the robust combined capabilities of The Specialty Alliance, Specialty Networks and Cardinal Health."

    "The formation of our Urology Alliance within The Specialty Alliance marks a significant step in expanding our multi-specialty model to meet patient needs across more communities," said Dr. Weber. "As a physician, I know firsthand that integrated, coordinated care is critical to improving outcomes. By bringing Solaris Health's leading urology network into our platform, we're helping specialty providers focus more of their time and energy where it matters most, on their patients. Together, we're advancing a model that empowers physicians and prioritizes the highest standards of care."

    "Joining The Specialty Alliance's Urology Alliance strengthens our ability to deliver exceptional, patient-centered care through a physician-led, national platform," said Gary Kirsh, MD, CEO, Solaris Health. "This partnership expands our collaborative network of urology providers, allowing physicians to optimize care delivery and enhance patient access to specialized services in their local communities."

    Following the closing of the transaction, Dr. Kirsh will retire from his role leading Solaris Health and serve as a Senior Advisor to Cardinal Health.

    "Lee Equity would like to thank Dr. Kirsh for his visionary leadership and congratulate him on building the leading platform in urology," said Christian Chauvet, Partner, Lee Equity. "Dr. Kirsh has been a steadfast champion of independent medicine for his entire career, and we are proud to see Solaris Health and its exceptional physician base continue this legacy by joining the Urology Alliance."

    Cardinal Health expects the transaction to close by the end of calendar year 2025, subject to closing conditions, including the receipt of required physician and regulatory approvals. The transaction is expected to be slightly accretive to Cardinal Health's non-GAAP earnings per share (EPS) in the first 12 months following close. Cardinal Health expects to include the expected impact to its fiscal year 2026 guidance after the acquisition is completed.

    Capital Deployment

    In connection with the announcement of the acquisition, Cardinal Health reaffirmed its disciplined capital allocation framework. The company intends to finance the acquisition with a combination of cash on hand and new debt financing and plans to take a focused approach to paying down debt over the next 18 to 24 months. The company does not expect its deleveraging plans to change its previously outlined share repurchases and continues to expect to be within its targeted leverage range by the end of fiscal 2026.

    Advisors

    Goldman Sachs served as financial advisor to Cardinal Health on the acquisition of Solaris Health and Skadden, Arps, Slate, Meagher & Flom LLP and Katten Muchin Rosenman LLP served as legal advisors on the transaction. Centerview Partners served as financial advisor to Solaris Health and McDermott, Will & Emery served as legal advisor on the transaction. Goldman Sachs, BofA Securities and Wells Fargo serve as lead advisors on financing matters related to the acquisition.

    About Cardinal Health

    Cardinal Health is a distributor of pharmaceuticals and specialty products; a global manufacturer and distributor of medical and laboratory products; a supplier of home-health and direct-to-patient products and services; an operator of nuclear pharmacies and manufacturing facilities; and a provider of performance and data solutions. Our company's customer-centric focus drives continuous improvement and leads to innovative solutions that improve people's lives every day. Learn more about Cardinal Health at cardinalhealth.com and in our Newsroom.

    About Solaris Health

    Solaris Health is the leading U.S. healthcare management company in the urological field. Its affiliated medical practices have over 750 providers who annually care for over one million unique patients in 14 states. These practices and their providers are committed to enhancing access to specialty healthcare and continually improving patient outcomes. Empowering community providers allows them to make sure that every decision they make puts patient care at the forefront. Solaris Health is growing to meet the changing needs of healthcare providers, and to help them develop innovative ways to better deliver value and state-of-the-art care to their patients. Solaris Health is proud to be among the most innovative healthcare management companies in the United States. To learn more, visit www.solarishealthpartners.com.

    About Lee Equity Partners, LLC

    Lee Equity Partners, LLC is a middle-market private equity firm that partners with businesses in the financial and healthcare services sectors. Over nearly two decades the firm has utilized its thematic based investment strategy and deep sector knowledge to identify and partner with talented management teams to accelerate growth and build market leading businesses. Additional information is available at leeequity.com.

    Contacts   

    Media: Erich Timmerman, [email protected] and (614) 553-3853 

    Investors: Matt Sims, [email protected] and (614) 553-3661 

    Cautions Concerning Forward-Looking Statements 

    This news release contains forward-looking statements addressing expectations, prospects, estimates and other matters that are dependent upon future events or developments. These statements may be identified by words such as "expect," "anticipate," "intend," "plan," "believe," "will," "should," "could," "would," "project," "continue," "likely," and similar expressions, and include statements reflecting future results or guidance, statements of outlook, and various accruals and estimates. These matters are subject to risks and uncertainties that could cause actual results to differ materially from those projected, anticipated or implied. These risks and uncertainties include risks associated with our planned acquisition of Solaris Health, including the risk that we may not receive required regulatory approval or physician consents or otherwise fail to complete the transaction; the risk that we may fail to realize the anticipated strategic and financial benefits of the acquisition, whether as a result of external factors that may impact the profitability of the business or due to unforeseen challenges. Cardinal Health is subject to additional risks and uncertainties described in Cardinal Health's Form 10-K, Form 10-Q and Form 8-K reports and exhibits to those reports. This news release reflects management's views as of August 12, 2025. Except to the extent required by applicable law, Cardinal Health undertakes no obligation to update or revise any forward-looking statement. Forward-looking statements are aspirational and not guarantees or promises that goals, targets or projections will be met, and no assurance can be given that any commitment, expectation, initiative or plan in this news release can or will be achieved or completed. 

     

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/cardinal-health-announces-the-addition-of-solaris-health-the-countrys-leading-urology-mso-to-the-specialty-alliance-302527186.html

    SOURCE Cardinal Health

    Get the next $CAH alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CAH

    DatePrice TargetRatingAnalyst
    6/3/2025$179.00Equal Weight → Overweight
    Wells Fargo
    2/5/2025$140.00 → $150.00Hold → Buy
    Jefferies
    1/8/2025$130.00 → $144.00Hold → Buy
    TD Cowen
    1/7/2025$140.00In-line → Outperform
    Evercore ISI
    1/6/2025$132.00 → $145.00Neutral → Buy
    BofA Securities
    12/13/2024$101.00 → $127.00Underweight → Equal Weight
    Wells Fargo
    12/4/2024$139.00Outperform
    Mizuho
    2/26/2024$125.00Outperform
    Leerink Partners
    More analyst ratings

    $CAH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Cardinal Health Board of Directors Approves Quarterly Dividend

    DUBLIN, Ohio, Aug. 15, 2025 /PRNewswire/ -- Cardinal Health (NYSE: CAH) announced today that its Board of Directors approved its quarterly dividend of $0.5107 per share, out of the Company's capital surplus. The dividend will be payable on October 15, 2025 to shareholders of record at the close of business on October 1, 2025. About Cardinal HealthCardinal Health is a distributor of pharmaceuticals and specialty products; a global manufacturer and distributor of medical and laboratory products; a supplier of home-health and direct-to-patient products and services; an operator o

    8/15/25 4:40:00 PM ET
    $CAH
    Other Pharmaceuticals
    Health Care

    Cardinal Health Reports Fourth Quarter and Fiscal Year 2025 Results and Raises Fiscal Year 2026 Guidance

    Fourth quarter revenue was relatively flat at $60.2 billion; revenue increased 21% excluding the impact of a previously communicated contract expirationFourth quarter GAAP1 operating earnings were $428 million and GAAP diluted EPS was $1.00Fourth quarter non-GAAP operating earnings increased 19% to $719 million and non-GAAP diluted EPS increased 13% to $2.08Fiscal Year 2025 adjusted free cash flow was $2.5 billionFiscal year 2026 non-GAAP EPS guidance2 raised to $9.30 to $9.50, from $9.10 to $9.30Company announces the acquisition of Solaris Health, the country's leading urology MSODUBLIN, Ohio, Aug. 12, 2025 /PRNewswire/ -- Cardinal Health (NYSE:CAH) today reported fourth quarter fiscal year

    8/12/25 6:55:00 AM ET
    $CAH
    Other Pharmaceuticals
    Health Care

    Cardinal Health announces the addition of Solaris Health, the country's leading urology MSO, to The Specialty Alliance

    Adds over 750 providers to Cardinal Health's multi-specialty MSO platform, The Specialty AllianceJoins with recent urology acquisitions to bolster The Specialty Alliance's leadership in the urology therapeutic areaCardinal Health MSO platforms reach ~3,000 providers in 32 states upon transaction close DUBLIN, Ohio, Aug. 12, 2025 /PRNewswire/ -- Cardinal Health (NYSE:CAH) today announced that The Specialty Alliance, its multi-specialty management services organization (MSO) platform, has entered into a definitive agreement to acquire Solaris Health, the country's leading urology MSO, from Lee Equity Partners and Solaris Health physician owners.

    8/12/25 6:45:00 AM ET
    $CAH
    Other Pharmaceuticals
    Health Care

    $CAH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Cardinal Health upgraded by Wells Fargo with a new price target

    Wells Fargo upgraded Cardinal Health from Equal Weight to Overweight and set a new price target of $179.00

    6/3/25 7:24:57 AM ET
    $CAH
    Other Pharmaceuticals
    Health Care

    Cardinal Health upgraded by Jefferies with a new price target

    Jefferies upgraded Cardinal Health from Hold to Buy and set a new price target of $150.00 from $140.00 previously

    2/5/25 7:09:45 AM ET
    $CAH
    Other Pharmaceuticals
    Health Care

    Cardinal Health upgraded by TD Cowen with a new price target

    TD Cowen upgraded Cardinal Health from Hold to Buy and set a new price target of $144.00 from $130.00 previously

    1/8/25 7:36:58 AM ET
    $CAH
    Other Pharmaceuticals
    Health Care

    $CAH
    SEC Filings

    View All

    SEC Form 8-K filed by Cardinal Health Inc.

    8-K - CARDINAL HEALTH INC (0000721371) (Filer)

    8/14/25 5:06:21 PM ET
    $CAH
    Other Pharmaceuticals
    Health Care

    SEC Form FWP filed by Cardinal Health Inc.

    FWP - CARDINAL HEALTH INC (0000721371) (Subject)

    8/13/25 4:44:29 PM ET
    $CAH
    Other Pharmaceuticals
    Health Care

    SEC Form 424B3 filed by Cardinal Health Inc.

    424B3 - CARDINAL HEALTH INC (0000721371) (Filer)

    8/13/25 8:51:32 AM ET
    $CAH
    Other Pharmaceuticals
    Health Care

    $CAH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Information Officer Greene Michelle D. was granted 16,362 shares, increasing direct ownership by 88% to 34,968 units (SEC Form 4)

    4 - CARDINAL HEALTH INC (0000721371) (Issuer)

    8/12/25 4:28:58 PM ET
    $CAH
    Other Pharmaceuticals
    Health Care

    CEO, PSS Segment Weitzman Deborah was granted 39,100 shares, increasing direct ownership by 80% to 88,229 units (SEC Form 4)

    4 - CARDINAL HEALTH INC (0000721371) (Issuer)

    8/12/25 4:19:07 PM ET
    $CAH
    Other Pharmaceuticals
    Health Care

    Chief Human Resources Officer Snow Ola M was granted 31,813 shares, increasing direct ownership by 135% to 55,351 units (SEC Form 4)

    4 - CARDINAL HEALTH INC (0000721371) (Issuer)

    8/12/25 4:17:58 PM ET
    $CAH
    Other Pharmaceuticals
    Health Care

    $CAH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Cardinal Health Inc. (Amendment)

    SC 13G/A - CARDINAL HEALTH INC (0000721371) (Subject)

    2/13/24 5:01:02 PM ET
    $CAH
    Other Pharmaceuticals
    Health Care

    SEC Form SC 13G/A filed by Cardinal Health Inc. (Amendment)

    SC 13G/A - CARDINAL HEALTH INC (0000721371) (Subject)

    1/30/24 1:39:03 PM ET
    $CAH
    Other Pharmaceuticals
    Health Care

    SEC Form SC 13G/A filed by Cardinal Health Inc. (Amendment)

    SC 13G/A - CARDINAL HEALTH INC (0000721371) (Subject)

    2/14/23 12:37:58 PM ET
    $CAH
    Other Pharmaceuticals
    Health Care

    $CAH
    Financials

    Live finance-specific insights

    View All

    Cardinal Health Board of Directors Approves Quarterly Dividend

    DUBLIN, Ohio, Aug. 15, 2025 /PRNewswire/ -- Cardinal Health (NYSE: CAH) announced today that its Board of Directors approved its quarterly dividend of $0.5107 per share, out of the Company's capital surplus. The dividend will be payable on October 15, 2025 to shareholders of record at the close of business on October 1, 2025. About Cardinal HealthCardinal Health is a distributor of pharmaceuticals and specialty products; a global manufacturer and distributor of medical and laboratory products; a supplier of home-health and direct-to-patient products and services; an operator o

    8/15/25 4:40:00 PM ET
    $CAH
    Other Pharmaceuticals
    Health Care

    Cardinal Health Reports Fourth Quarter and Fiscal Year 2025 Results and Raises Fiscal Year 2026 Guidance

    Fourth quarter revenue was relatively flat at $60.2 billion; revenue increased 21% excluding the impact of a previously communicated contract expirationFourth quarter GAAP1 operating earnings were $428 million and GAAP diluted EPS was $1.00Fourth quarter non-GAAP operating earnings increased 19% to $719 million and non-GAAP diluted EPS increased 13% to $2.08Fiscal Year 2025 adjusted free cash flow was $2.5 billionFiscal year 2026 non-GAAP EPS guidance2 raised to $9.30 to $9.50, from $9.10 to $9.30Company announces the acquisition of Solaris Health, the country's leading urology MSODUBLIN, Ohio, Aug. 12, 2025 /PRNewswire/ -- Cardinal Health (NYSE:CAH) today reported fourth quarter fiscal year

    8/12/25 6:55:00 AM ET
    $CAH
    Other Pharmaceuticals
    Health Care

    Cardinal Health Board of Directors Approves Quarterly Dividend

    DUBLIN, Ohio, May 5, 2025 /PRNewswire/ -- Cardinal Health (NYSE:CAH) announced today that its Board of Directors approved an increase to its quarterly dividend, to $0.5107 per share, out of the Company's capital surplus. The dividend will be payable on July 15, 2025, to shareholders of record at the close of business on July 1, 2025. About Cardinal HealthCardinal Health is a distributor of pharmaceuticals and specialty products; a global manufacturer and distributor of medical and laboratory products; a supplier of home-health and direct-to-patient products and services; an op

    5/5/25 5:30:00 PM ET
    $CAH
    Other Pharmaceuticals
    Health Care

    $CAH
    Leadership Updates

    Live Leadership Updates

    View All

    After Major Oncology Conference, All Eyes Turn to Industry Innovation

    USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 12, 2025 /PRNewswire/ -- After the close of the world's largest cancer conference (the 2025 American Society of Clinical Oncology annual meeting), doctors, scientists, and researchers are optimistic, especially in the fields of immunotherapy, Car T-cell therapy, liquid biopsies, breast cancer, AI, and even exercise. However, with reports coming out that the current US administration could drastically reduce funding of the National Cancer Institute (NCI) by nearly 40%, the market is looking towards the private sector to pick up the slack and continue to make advancements in cancer treatment. For inv

    6/12/25 9:00:00 AM ET
    $CAH
    $CTOR
    $CTXR
    Other Pharmaceuticals
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Carlisle Companies Announces Leadership Appointments

    Carlisle Companies Incorporated (NYSE:CSL) today announced the appointment of Christopher B. Gaskill as Vice President & General Counsel for the Company. In conjunction with this appointment, Scott C. Selbach will transition to a new role as Executive Vice President, Government Relations for the Company. Mr. Selbach will also remain Secretary of the Company. Both Mr. Gaskill and Mr. Selbach will report to Chris Koch, Carlisle's Chair, President & Chief Executive Officer. Prior to joining Carlisle, Mr. Gaskill served as Executive Vice President, Chief Legal Officer, and Secretary at Summit Materials, Inc. (NYSE:SUM), where he was responsible for the company's global legal functions and ensu

    5/16/25 4:05:00 PM ET
    $CAH
    $CSL
    $SUM
    Other Pharmaceuticals
    Health Care
    Specialty Chemicals
    Industrials

    Robert Musslewhite and Sudhakar Ramakrishna to join Cardinal Health Board of Directors

    DUBLIN, Ohio, March 10, 2025 /PRNewswire/ -- Cardinal Health (NYSE:CAH) announced today that its Board of Directors has elected Robert Musslewhite, former Chief Executive Officer of Definitive Healthcare Corp., and Sudhakar Ramakrishna, President and Chief Executive Officer of SolarWinds Corporation, as independent directors, effective March 7, 2025. With more than 20 years of leadership experience, including serving as CEO for two publicly traded companies, Mr. Musslewhite brings to the board unique expertise in advanced analytics, data, and technology across the healthcare e

    3/10/25 6:45:00 AM ET
    $CAH
    Other Pharmaceuticals
    Health Care